Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05513872 · ClinicalTrials.gov registry record · Phase 1

Overcoming Nicotine Dependence to Enable Quitting

A Phase 1 study of Smoking Cessation and Tobacco Use, sponsored by Rush University Medical Center.

Recruiting
Registry status
Phase 1
Development phase
780
Enrollment target
1
Study location

NCT05513872: Recruiting Phase 1 study of Smoking Cessation and Tobacco Use, sponsored by Rush University Medical Center.

NCT05513872 is a Phase 1 study of Smoking Cessation and Tobacco Use that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 780 participants, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05513872, a Phase 1 study of Smoking Cessation and Tobacco Use, is actively recruiting participants, sponsored by Rush University Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
780 participants
Enrollment target
1
Study location

Study Summary

Tobacco use disorder is a chronic, relapsing health condition that necessitates a chronic care approach. However, traditional smoking cessation treatment programs allocate nearly all their resources only to those smokers who are willing to set a quit date. This is problematic because few smokers are ready to set a quit date at any given time, and a smoker's stated intention to quit can change rapidly. One novel potential treatment strategy is to foster practice quitting (PQ), defined as attempting to not smoke for a few hours or days, without pressure or expectation to permanently quit. Although a growing body of evidence supports the role of practice quitting in fostering permanent quit attempts and cessation, there is a significant knowledge gap regarding which treatment strategies should be used to engage smokers in practice quitting. The proposed study will test the role of PQ counseling vs. Motivational Interviewing (MI) counseling, and NRT sampling (four-week supply of nicotine lozenges and patches) vs. none.

Primary Outcome

Intentional abstinence of ≥ 24 hours between the end of treatment and the 6-month follow-up assessment

Interventions

  • DRUG Nicotine Replacement Therapy (NRT) Sampling
  • BEHAVIORAL Practice Quitting (PQ) Counseling
  • BEHAVIORAL Motivational Interviewing (MI) Counseling

Study Locations (1)

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 780 participants
Start Date 2023-03-24
Est. Completion 2027-08-30
Phase Phase 1
Rush University Medical Center

320 total trials

What NCT05513872 shows while recruiting

NCT05513872 is an interventional study that assigns participants to a tested intervention. The registered 780 participants enrollment target is mid-sized for trials with a published cap, above the 471-participant average among 188 other Smoking Cessation trials with a reported enrollment target (66% higher).

The record links to 5 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which Nicotine Replacement Therapy (NRT) Sampling is the first listed.

NCT05513872 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05513872 about?

NCT05513872 is a clinical study titled "Overcoming Nicotine Dependence to Enable Quitting". Tobacco use disorder is a chronic, relapsing health condition that necessitates a chronic care approach. However, traditional smoking cessation treatment programs allocate nearly all their resources only to those smokers who are willing to set a quit date. This is problematic because few smokers are...

What is the current status of trial NCT05513872?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 780 participants. The study started on 2023-03-24. Estimated completion is 2027-08-30.

What conditions does trial NCT05513872 study?

This clinical trial studies the following conditions: Smoking Cessation, Tobacco Use, Nicotine Dependence, Smoking Behaviors, Nicotine Withdrawal.

What interventions are being tested in trial NCT05513872?

The interventions under investigation include: Nicotine Replacement Therapy (NRT) Sampling (DRUG), Practice Quitting (PQ) Counseling (BEHAVIORAL), Motivational Interviewing (MI) Counseling (BEHAVIORAL).

Who is sponsoring clinical trial NCT05513872?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05513872 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05513872's enrollment target sits among peer trials

780 32nd of 188 higher than 157 of 188 other Smoking Cessation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05046613 · 780 participants

    Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

  • NCT05100862 · 780 participants · Phase 3

    A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

  • NCT06310031 · 780 participants · NA

    Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

  • NCT06312137 · 780 participants · Phase 3

    A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05513872, the US trial registry maintained by the National Library of Medicine. NCT05513872 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.